chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This was the Booster Pfizer shot given to those with serious health issues.  About a week later, 9/2/21 he had red blotches on both arms starting at the top of his hands to his shoulders on both sides of both arms.    They are not itchy.
pt recvd vax 10OCT94 no adverse rxn's; SIDS death;
Narrative:  This 64 year old MALE patient presents to the ER with a complaint of chest pain following initial covid vaccination. PT states that he was waiting his 15 minutes after receiving his covid vaccine. PT started to get up and felt a global weakness in his body. PT had some mild chest pressure, 4/10, that lasted until he got to the ED, improved upon arrival. No pain at time of MD assessment: "It felt like I had worked out or something." Resolved upon arrival to the ED. No sob. no tongue swelling or swelling in mouth. no rash. no difficulty breathing. No hx of CAD. No recent stress test. No hx of covid per pt. PT symptom free at this time.
Swollen lymph nodes; mild dry cough after 2nd dose; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  An 18-year-old male patient received BNT162b2 (BNT162B2), on 05Jul2021 as dose 2, single (Lot number: EW0179) at the age of 18 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: BNT162b2 (Prev dose lot number: EW0183, Prev dose dose number: 1, Prev dose vaccine location: Left arm), administration date: 14Jun2021, when the patient was 18-year-old, for COVID-19 Immunization.  The following information was reported: LYMPHADENOPATHY (hospitalization, life threatening) with onset Dec2021, outcome "not recovered", described as "Swollen lymph nodes"; COUGH (hospitalization, life threatening) with onset Dec2021, outcome "not recovered", described as "mild dry cough after 2nd dose". The patient was hospitalized for lymphadenopathy, cough (hospitalization duration: 4 day(s)). The events "swollen lymph nodes" and "mild dry cough after 2nd dose" required physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Apr2022) Negative; (Dec2021) Negative. It was unknown if therapeutic measures were taken as a result of lymphadenopathy, cough.   Clinical course: It was reported that the patient did not had COVID prior vaccination and since the vaccination, the patient was tested for COVID-19. The patient had no known allergies. It was unknown if other vaccine in four weeks. It was reported that the patient had swollen lymph nodes and mild dry cough after 2nd dose. After receiving Mandatory Booster for College red blood cell and hemoglobin counts irregular. Required blood transfusions. Diagnosis is Lymphoma. only treatment is chemotherapy. Now also have stepping gait/drop foot.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202200952509 same patient and product, different dose and different events;
I was not told if it was SHINGRIX or ZOSTAVAX. I had symptoms after both shots. The first was 7/24/2018. The next day I had severe fatigue, body aches, nausea and flu like symptoms, in addition to soreness at the site. The second shot, a few hours later I developed a fever, was shivering. My face hands and feet were bright red, and I was generally achy all over, with an especially bad backache.
15 minutes after the vaccine L arm tingling to hand then sensation change in upper shoulder neck and back. Face numb feeling, then upper and lower back affected and painful as "nerve pain"  Pain going to right and left leg shin areas. Has doctor appt on 5/24/2017.
Local reaction rt deltoid; c/o vomiting, dehydration, cold sweats; pain in mid abd., freq. urination.
I have mild psoriatic arthritis mostly affecting hands. Two days after vaccinated I noticed increase inflammation, itching with small skin blisters appearing to my palms and fingers. About week later, notice feet started itching, small skin blisters appeared, mostly at sides around the arch and heel. Usually flareup is minor with small patches subsiding after two days. Since receiving Shingrix vaccine, increase of my arthritis inflammation does not seem to subside. My finger joints continue to stay inflamed and occasional small breaks in the skin develop. My psoriasis treatment is topical steroid and UVB light.
About 1/2 hour after vaccine pt reported a funny taste in her mouth; a metallic taste.
On day 1 of injection around lunch time, the patient was okay. On day 2 morning, she had a pea sized bump and she had reported that she suffered diarrhea, sweat, fever and body pain. On day 3, patient stated the bumps around injection site has spread to a size of an orange. On day 4, patient visited store and shown me her orange size bumps. These bumps are fairly big in size and reddish in color.
Administration date=13Jan2021, dose number=2/ administration date=21Dec2020, dose number=1; Starting 36 hr after 2nd dose had 4 days of whole body systemic hives, itching; Starting 36 hr after 2nd dose had 4 days of whole body systemic hives, itching; This is a spontaneous report from a contactable nurse. A 48-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL0142), via an unspecified route of administration on the Right arm on 13Jan2021 07:45 at a SINGLE DOSE for covid-19 immunisation. Medical history included drug hypersensitivity from an unknown date and unknown if ongoing, hypothyroidism from an unknown date and unknown if ongoing. Concomitant medication included levothyroxine sodium (SYNTHROID). The patient had the first dose of BNT162B2 on 21Dec2020. On 15Jan2021 03:00 PM, starting 36 hours after 2nd dose, the patient had 4 days of whole body systemic hives and itching. There were no respiratory symptoms. Therapeutic measures (Pepcid, Zantac, Benadryl oral and cream) were taken as a result of hives and itching. The outcome of the events was recovered on an unspecified date.
Information has been received from a consumer concerning an approx. 3 year old female who in approx. 2000, was vaccinated with a dose of MMRII. Two weeks, post vax, the pt developed some undefined neurological problems. It was reported that she can not walk or talk, her face is expressionless and she is on tube feedings. It was reported that the pt had tests performed at a hospital. At the time of this report, it was reported that the pt is 5 years old and some days she will wake up and walk normally, but then she regresses. The pt's family believes that the pt's "neurological events" may be due to the Mercury in MMRII. Upon internal medical review, the pt's events; she can not walk, can not talk, her face is expressionless and being on tube feedings were considered "Other Important Medical Events". Additional information has been requested.
pt slept from time p/shot from 330 29AUG94 until 11AM; pt whined during noc; APAP given; MD called; t103;
dizziness; Headache; Nausea; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 56 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 21Jan2021 10:00 (Lot number: EL3302) at the age of 56 years as dose 1, 0.3 ml single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DIZZINESS (non-serious) with onset 21Jan2021 09:50, outcome "recovered" (2021), described as "dizziness"; HEADACHE (non-serious) with onset 21Jan2021 09:50, outcome "recovered" (2021), described as "Headache"; NAUSEA (non-serious) with onset 21Jan2021 09:50, outcome "recovered" (15Feb2021), described as "Nausea". Therapeutic measures were not taken as a result of dizziness, headache. Therapeutic measures were taken as a result of nausea.  Additional information:1st vaccine dose, had mild side effect. 2nd vaccine dose, nausea, vomiting, fever, body aches, chills, headaches lasted 3 days from date of 2nd vaccination administration consulted with physician nurse on 11Feb2021 and with physician via E-visit on 12Feb2021 due to side effect medication was prescribed for nausea and vomiting.  No follow-up attempts are possible. No further information is expected.
Local reaction-swelling/induration of 4.5x6cm on arm.  Swelling almost gone by 05/10/04.
Severe body aches; Chills; Sleeplessness; Sweats; Mental fog; Headache; Nausea; This is a spontaneous report from a contactable Non-Health care professional, the patient. A 65-year-old patient of an unspecified gender received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the left arm on 26Feb2021 at 09:45 (at the age of 65-years-old), as a second single dose for COVID-19 vaccination and received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN9581) via an unspecified route of administration in the left arm on 05Feb2021 at 10:15 (at the age of 65-years-old), as a first single dose for COVID-19 vaccination The patient's medical history was not provided. The patient did not have any allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with Covid-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications were not provided. The patient did not receive any other vaccine within 4 weeks prior to the vaccine. On 27Feb2021 at 00:00, the patient experienced headache, nausea followed by chills, sweats, severe body aches, sleeplessness, and mental fog for 72 hours. However, the headache and nausea did not abate. The patient received the treatment for the adverse events and was still under the treatment at the time of the report. The patient was testing for temporal arteri. The clinical outcome of headache, nausea, chills, sweats, severe body aches, sleeplessness and mental fog was not recovered. No follow-up attempts are needed. No further information is expected.
I became very nauseous and fainted as I exited the doctor's office about 20 minutes after administration of the vaccine. When I awoke after fainting I was still very nauseous and was sweating profusely.
Injection site warm to touch; Bright red rash close to injection site; Injection site aching; Soreness of arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Soreness of arm), INJECTION SITE WARMTH (Injection site warm to touch), INJECTION SITE RASH (Bright red rash close to injection site) and INJECTION SITE PAIN (Injection site aching) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Feb-2021, the patient experienced PAIN IN EXTREMITY (Soreness of arm). On 14-Feb-2021, the patient experienced INJECTION SITE WARMTH (Injection site warm to touch), INJECTION SITE RASH (Bright red rash close to injection site) and INJECTION SITE PAIN (Injection site aching). At the time of the report, PAIN IN EXTREMITY (Soreness of arm) had resolved and INJECTION SITE WARMTH (Injection site warm to touch), INJECTION SITE RASH (Bright red rash close to injection site) and INJECTION SITE PAIN (Injection site aching) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Her doctor told her to take Prednisone 20 mg three times daily and Generic Bactrim 1 tablet twice per day.  Her doctor also asked her to call Moderna regarding treatment recommendation regarding her side effects. She thought  the 60 mg of Prednisone is too much for her to take. No concomitant medications reported by investigator
I love the vaccine I think it?s great, but I have been having heart palpitations which resulted in hospitalization 4 times, migraines, blurry vision, numbness in my limbs, i?m unable to drink coffee without having extreme anxiety. This has been going on for 6 months with no relief
My daughter started feeling extreme dizziness and profane sweating 30s - 1 minutes.  after her shot. She needed to rest in the pharmacy for 30min before they were able to leave. She had high fever for 4 days, dizziness (2 days), and redness/rash for 5 days. She is still not fully recovered.
Cardiogenic shock temporally associated with COVID-19 vaccination; This is a literature report.  A 21 year-old male patient received bnt162b2 (BNT162B2), administration date 05Nov2021 (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. Relevant medical history included: "COVID-19 infection" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: CARDIOGENIC SHOCK (medically significant), outcome "unknown", described as "Cardiogenic shock temporally associated with COVID-19 vaccination". The patient underwent the following laboratory tests and procedures: blood culture: no growth, notes: No growth; blood thyroid stimulating hormone: 1.95, notes: 1.95 µIU/mL; coxsackie virus test negative: negative; coxsackie virus test positive: positive; cytomegalovirus test: negative; gastrointestinal pathogen panel: positive, notes: Positive for Campylobacter species; hepatitis c antibody negative: negative; hiv antibody negative: negative; legionella test: negative; sars-cov-2 antibody test: positive; sars-cov-2 test: negative, notes: Day 1 of admission Negative Day 7 of admission Negative.  The lot number for [bnt162B2], was not provided and will be requested during follow up.; Sender's Comments: As there is limited information in the case provided, the causal association between the event and the suspect drug BNT162B2 cannot be excluded. The case will be reassessed once new information is available.  The impact of this report on the benefit-risk profile of the Pfizer product and on the conduct of the study is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
Pale and gray after a nap, briefly resumed color but then began to become cyanotic. Ambulance was called they also noted pt to be cyanotic and very sleepy, pulse ox unable to read SP02, placed on blow by O2, entire episode is approximated to have lasted for 15 minutes.
A physician reported that a 30 year old female received an injection of vaccine, in November, 1990. In January, 2001, the patient was hospitalized for the diagnosis of pneumococcal sepsis, serotype 9N. While hospitalized, the patient was ventilator dependent for 3 days and had no urine output for 2 days. The reporter did note that the patient had received and injection of pneumococcal vaccine in September, 2000. Follow up information received on 04/04/2001, indicated that this patient was 31 years old and was hospitalized for more than 30 days. Upon further medical review the code of intubation NOS was removed from the case.
To ED with generalized weakness and fatigue. S/P CABG over 30 days ago. Admitted and monitored on telemetry. Acute on chronic systolic CHF initially received diuresis with Cardiology consult. Developed acute kidney injury and nephrology consulted. Gentle IV fluids and renal function normalized. Restarted oral diuretics.. Continued weakness and deconditioning-UTI completed full course of antibiotics with Rocephi. COVID (+) during hospitalization but showed no signs of cold symptomology. Placed in isolation per CDC guidelines. Transferred to REHAB on discharge.
My appetite has been suppressed, since receiving the booster; Dose number: 3; This is a spontaneous report from a contactable reporter (pharmacist). The reporter is the patient.  A 43-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in right arm, administration date 11Dec2021 at 12:00 (Lot number: unknown) at the age of 43 years as dose 3 (booster), single for COVID-19 immunisation. The patient had no relevant medical history. Concomitant medication included: LEXAPRO. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE; Lot number: Unknown; Anatomical location: Right Arm, Administration Time: 09:00), administration date: 07Feb2021, when the patient was 42 years old, for COVID-19 immunisation and Bnt162b2 (DOSE 2, SINGLE; Lot number: Unknown; Anatomical location: Right Arm, Administration Time: 09:00), administration date: 27Feb2021, when the patient was 42 years old, for COVID-19 immunisation. The following information was reported: IMMUNISATION (non-serious) with onset 11Dec2021 at 12:00, outcome "unknown", described as "Dose number: 3"; DECREASED APPETITE (non-serious) with onset 13Dec2021 at 00:00, outcome "recovering", described as "My appetite has been suppressed, since receiving the booster". Therapeutic measures were not taken as a result of decreased appetite.  Additional information: The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had not been tested for COVID-19.   The lot number for BNT162b2 was not provided and will be requested during follow up.
Pt vaccinated w/DTP/OPV/HIBTiter developed fever 104.
102 Temp,  Uncontrollable chills Headache Aches all over
pt recvd vax for prophylaxis & 5 days p/ 2nd dose, exp nausea, v, fever & elevated liver func tests; unresolved
Rash started at neck and traveled down torso to legs and feet; fever reached 101.5; gave Tylenol and rash went away on its own.
Area around the injection site has reddened and is extremely itchy.  Began  Thursday. Doesn't itch all the time. Does not interfere with daily routine or sleep.
No adverse reactions have been noted by patient or family. This information is current as of November 14, 2021, 11PM Central.
Pt passed out. Woke up immediately after passing out, Blood pressure was normal including orthostatics and and blood sugar was normal as well. Pt reported no pain to vaccine administration.
10/04/1996 - pt received second dose of varicella virus vaccine live; 10/28/1999 pt arrived at day care with a raised rash on his arms, back and legs; 10/29/1999 pt was diagnosed in the ER with chickenpox.
This spontaneous report as received from a health care professional refers to unspecified number of patients. This is a market research program. The reporter stated that in his/her hospital they decided to administer PNEMOVAX 23 (dose, route, lot number and expiration date were not provided) with PREVNAR 13 to at least some adult patients because PREVNAR 13 protected them against 13 strains which are not in PNEUMOVAX 23. Patient's outcomes were unknown. Additional information has been requested.
Pt recvd vax 13AUG91 & 14AUG92 pt devel fever of 102; devel area of erythema & induration @ inject site measuring about 6mc in diameter; area was hot to the touch; pt hospitalized;
Approx 14 hours post vax was woken up with nausea. Vomited once. Couldn?t sleep. Vomited again approx 18 hours post vax. Started running a fever of 101.5 after second vomit episode.
Patient reports 2 days post-first shot of Pfizer that her bottom lip swelled and her skin itched all over. She reports she developed hives from head-to--toe when she scratched her skin. She denies feeling as if her throat was closing or difficulty breathing. Patient reports taking a shower and her skin felt like it was burning. This lasted for 4 days and she did not use oral or topical medications.
shivering; headache; muscle pain; This case was reported by a consumer via call center representative and described the occurrence of shivering in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 9th January 2020, the patient received Shingrix. On 10th January 2020, 1 days after receiving Shingrix, the patient experienced shivering, headache and muscle pain. On an unknown date, the outcome of the shivering, headache and muscle pain were unknown.   It was unknown if the reporter considered the shivering, headache and muscle pain to be related to Shingrix.  Additional details were received as follows: The age at vaccination was not reported.
This spontaneous report as received from a pharmacy technician refers to a 3 year old patient of unknown gender. Patient's concurrent conditions, medical history, concomitant medications, drug reactions and allergies were not reported. On 25-JAN-2018, the patient was vaccinated with improperly stored dose of Oka/Merck VARIVAX (lot # N022979, expiry 23-AUG-2019) for prophylaxis. No adverse effect was reported. The Oka/Merck VARIVAX temperature excursion occurred on 14-DEC-2017 and 30-DEC-2017. On 14-DEC-2017, the vaccine was exposed to the temperature of 16.9 degree Fahrenheit (F) for 30 minutes. On 30-DEC-2017, the vaccine was exposed to the temperature of 6 degree Fahrenheit (F) to 14 degree F for 30 minutes. It was reported that the event was because of data logger. No product quality complaint was involved. This is one of the several reports received from the same reporter source. Sender's Comments: US-009507513-1802USA001558.
bruise; rash on arm at injection site/started like the size of a quarter now its tripled in size; mild itching; Sore for 2-3 days; This spontaneous case was reported by a consumer and describes the occurrence of CONTUSION (bruise), INJECTION SITE RASH (rash on arm at injection site/started like the size of a quarter now its tripled in size), PRURITUS (mild itching) and VACCINATION SITE PAIN (Sore for 2-3 days) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L20A) for COVID-19 vaccination.     Concomitant products included DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for an unknown indication.  On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Jan-2021, the patient experienced INJECTION SITE RASH (rash on arm at injection site/started like the size of a quarter now its tripled in size), PRURITUS (mild itching) and VACCINATION SITE PAIN (Sore for 2-3 days). On an unknown date, the patient experienced CONTUSION (bruise). At the time of the report, CONTUSION (bruise), INJECTION SITE RASH (rash on arm at injection site/started like the size of a quarter now its tripled in size), PRURITUS (mild itching) and VACCINATION SITE PAIN (Sore for 2-3 days) outcome was unknown.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.  The patient reported that her pharmacist recommended her to use Benadryl at night and her doctor had advised to put ice on it.